Skip to main content

Advertisement

SpringerLink
Log in

Combination therapy with risedronate and teriparatide in male osteoporosis

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Most studies of combination therapy with teriparatide and a bisphosphonate have not shown greater efficacy over monotherapy. The bisphosphonate risedronate, has not been studied in this context. The purpose of this proof-of-concept study was to assess whether combination risedronate and teriparatide increases bone mineral density (BMD) more than monotherapy with either drug alone. This was a randomized, double-blinded study of risedronate (35 mg weekly plus placebo injection), teriparatide (20 μg subcutaneously daily plus placebo tablet), or both risedronate plus teriparatide (combination) for 18 months in 29 men with low BMD. The primary endpoint was percentage change in lumbar spine (LS) BMD at 18 months. Secondary outcomes included changes in bone markers and BMD at other sites and interim time-points. All therapies increased LS BMD as compared with baseline (p < 0.05), but there were no between-group differences at 18 months. Total hip (TH) BMD increased to a greater extent in the combination group (mean ± SEM, 3.86 ± 1.1 %) versus teriparatide (0.29 ± 0.95 %) or risedronate (0.82 ± 0.95 %; p < 0.05 for both). Femoral neck (FN) BMD also increased more in the combination group (8.45 ± 1.8 %) versus risedronate (0.50 ± 1.7 %; p = 0.002), but was not different from teriparatide alone. In the combination group, P1NP and CTX increased rapidly, mirroring the teriparatide-alone arm. There were no between-group differences in adverse events. Combination teriparatide and risedronate increased BMD at the LS, TH as well as the FN and provided greater BMD increases at the TH than monotherapy. The results suggest combination risedronate and teriparatide therapy holds promise as a treatment for osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. R. Eastell, I.T. Boyle, J. Compston, C. Cooper, I. Fogelman, R.M. Francis, D.J. Hosking, D.W. Purdie, S. Ralston, J. Reeve, D.M. Reid, R.G. Russell, J.C. Stevenson, Management of male osteoporosis: report of the UK Consensus Group. QJM 91(2), 71–92 (1998)

    Article  PubMed  CAS  Google Scholar 

  2. O. Johnell, J.A. Kanis, An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17(12), 1726–1733 (2006). doi:10.1007/s00198-006-0172-4

    Article  PubMed  CAS  Google Scholar 

  3. J.R. Center, T.V. Nguyen, D. Schneider, P.N. Sambrook, J.A. Eisman, Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353(9156), 878–882 (1999). doi:10.1016/S0140-6736(98)09075-8

    Article  PubMed  CAS  Google Scholar 

  4. J.A. Kanis, G. Bianchi, J.P. Bilezikian, J.M. Kaufman, S. Khosla, E. Orwoll, E. Seeman, Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos. Int. 22(11), 2789–2798 (2011). doi:10.1007/s00198-011-1632-z

    Article  PubMed  CAS  Google Scholar 

  5. E.S. Kurland, F. Cosman, D.J. McMahon, C.J. Rosen, R. Lindsay, J.P. Bilezikian, Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J. Clin. Endocrinol. Metab. 85(9), 3069–3076 (2000)

    Article  PubMed  CAS  Google Scholar 

  6. E.S. Orwoll, W.H. Scheele, S. Paul, S. Adami, U. Syversen, A. Diez-Perez, J.M. Kaufman, A.D. Clancy, G.A. Gaich, The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J. Bone Miner. Res. 18(1), 9–17 (2003). doi:10.1359/jbmr.2003.18.1.9

    Article  PubMed  CAS  Google Scholar 

  7. E. Orwoll, M. Ettinger, S. Weiss, P. Miller, D. Kendler, J. Graham, S. Adami, K. Weber, R. Lorenc, P. Pietschmann, K. Vandormael, A. Lombardi, Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343(9), 604–610 (2000). doi:10.1056/NEJM200008313430902

    Article  PubMed  CAS  Google Scholar 

  8. S. Boonen, E.S. Orwoll, D. Wenderoth, K.J. Stoner, R. Eusebio, P.D. Delmas, Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J. Bone Miner. Res. 24(4), 719–725 (2009). doi:10.1359/jbmr.081214

    Article  PubMed  CAS  Google Scholar 

  9. E.S. Orwoll, P.D. Miller, J.D. Adachi, J. Brown, R.A. Adler, D. Kendler, C. Bucci-Rechtweg, A. Readie, P. Mesenbrink, R.S. Weinstein, Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J. Bone Miner. Res. 25(10), 2239–2250 (2010). doi:10.1002/jbmr.119

    Article  PubMed  CAS  Google Scholar 

  10. G. Mazziotti, J. Bilezikian, E. Canalis, D. Cocchi, A. Giustina, New understanding and treatments for osteoporosis. Endocrine 41(1), 58–69 (2012). doi:10.1007/s12020-011-9570-2

    Article  PubMed  CAS  Google Scholar 

  11. J.S. Finkelstein, A. Hayes, J.L. Hunzelman, J.J. Wyland, H. Lee, R.M. Neer, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N. Engl. J. Med. 349(13), 1216–1226 (2003). doi:10.1056/NEJMoa035725NEJMoa035725

    Article  PubMed  CAS  Google Scholar 

  12. J.S. Finkelstein, B.Z. Leder, S.M. Burnett, J.J. Wyland, H. Lee, A.V. de la Paz, K. Gibson, R.M. Neer, Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J. Clin. Endocrinol. Metab. 91(8), 2882–2887 (2006). doi:10.1210/jc.2006-0190

    Article  PubMed  CAS  Google Scholar 

  13. J.S. Finkelstein, J.J. Wyland, H. Lee, R.M. Neer, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 95(4), 1838–1845 (2010). doi:10.1210/jc.2009-1703

    Article  PubMed  CAS  Google Scholar 

  14. D.M. Black, S.L. Greenspan, K.E. Ensrud, L. Palermo, J.A. McGowan, T.F. Lang, P. Garnero, M.L. Bouxsein, J.P. Bilezikian, C.J. Rosen, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med. 349(13), 1207–1215 (2003). doi:10.1056/NEJMoa031975NEJMoa031975

    Article  PubMed  CAS  Google Scholar 

  15. J. Compston, The use of combination therapy in the treatment of postmenopausal osteoporosis. Endocrine 41(1), 11–18 (2012). doi:10.1007/s12020-011-9554-2

    Article  PubMed  CAS  Google Scholar 

  16. C. Deal, M. Omizo, E.N. Schwartz, E.F. Eriksen, P. Cantor, J. Wang, E.V. Glass, S.L. Myers, J.H. Krege, Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. J. Bone Miner. Res. 20(11), 1905–1911 (2005). doi:10.1359/JBMR.050714

    Article  PubMed  CAS  Google Scholar 

  17. G.H. Nancollas, R. Tang, R.J. Phipps, Z. Henneman, S. Gulde, W. Wu, A. Mangood, R.G. Russell, F.H. Ebetino, Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38(5), 617–627 (2006). doi:10.1016/j.bone.2005.05.003

    Article  PubMed  CAS  Google Scholar 

  18. C.J. Rosen, M.C. Hochberg, S.L. Bonnick, M. McClung, P. Miller, S. Broy, R. Kagan, E. Chen, R.A. Petruschke, D.E. Thompson, A.E. de Papp, Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J. Bone Miner. Res. 20(1), 141–151 (2005). doi:10.1359/JBMR.040920

    Article  PubMed  CAS  Google Scholar 

  19. S.L. Bonnick, C.C. Johnston Jr, M. Kleerekoper, R. Lindsay, P. Miller, L. Sherwood, E. Siris, Importance of precision in bone density measurements. J Clin Densitom 4(2), 105–110 (2001)

    Article  PubMed  CAS  Google Scholar 

  20. H.K. Genant, C.Y. Wu, C. van Kuijk, M.C. Nevitt, Vertebral fracture assessment using a semiquantitative technique. J. Bone Miner. Res. 8(9), 1137–1148 (1993). doi:10.1002/jbmr.5650080915

    Article  PubMed  CAS  Google Scholar 

  21. F. Cosman, E.F. Eriksen, C. Recknor, P.D. Miller, N. Guanabens, C. Kasperk, P. Papanastasiou, A. Readie, H. Rao, J.A. Gasser, C. Bucci-Rechtweg, S. Boonen, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis. J. Bone Miner. Res. 26(3), 503–511 (2011). doi:10.1002/jbmr.238

    Article  PubMed  CAS  Google Scholar 

  22. R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344(19), 1434–1441 (2001)

    Article  PubMed  CAS  Google Scholar 

  23. B. Borah, T. Dufresne, J. Nurre, R. Phipps, P. Chmielewski, L. Wagner, M. Lundy, M. Bouxsein, R. Zebaze, E. Seeman, Risedronate reduces intracortical porosity in women with osteoporosis. J. Bone Miner. Res. 25(1), 41–47 (2010). doi:10.1359/jbmr.090711

    Article  PubMed  CAS  Google Scholar 

  24. P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93(10), 3785–3793 (2008). doi:10.1210/jc.2008-0353

    Article  PubMed  CAS  Google Scholar 

  25. D. Gatti, O. Viapiana, S. Adami, L. Idolazzi, E. Fracassi, M. Rossini, Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3), 739–742 (2012). doi:10.1016/j.bone.2011.11.028

    Article  PubMed  CAS  Google Scholar 

  26. S.A. Polyzos, A.D. Anastasilakis, C. Bratengeier, W. Woloszczuk, A. Papatheodorou, E. Terpos, Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women—the six-month effect of risedronate and teriparatide. Osteoporos. Int. 23(3), 1171–1176 (2012). doi:10.1007/s00198-010-1525-6

    Article  PubMed  CAS  Google Scholar 

  27. J.F. Griffith, H.K. Genant, New advances in imaging osteoporosis and its complications. Endocrine 42(1), 39–51 (2012). doi:10.1007/s12020-012-9691-2

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This investigator-initiated study was originally funded by The Alliance for Better Bone Health (Procter and Gamble-Sanofi-Aventis) and then by Warner Chilcott and Sanofi. Study drugs were supplied by Procter and Gamble (Risedronate) and Eli Lilly (Teriparatide).

Disclosure

JPB was previously a consultant for The Alliance for Better Bone Health (Procter and Gamble-Sanofi-Aventis) and Warner Chilcott; JPB is a consultant for Amgen, Eli Lilly, Merck, Novartis, NPS Pharmaceuticals, and Radius. JPB receives research support from Amgen, NPS Pharmaceuticals and Warner Chilcott. No conflicts of interest reported for the remaining authors.

Author information

Authors and Affiliations

  1. Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 West 168th Street, PH 8W-864, New York, NY, 10032, USA

    Marcella D. Walker, Natalie E. Cusano, James Sliney Jr., Megan Romano, Chiyuan Zhang, Donald J. McMahon & John P. Bilezikian

Authors
  1. Marcella D. Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalie E. Cusano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James Sliney Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Megan Romano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chiyuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Donald J. McMahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. John P. Bilezikian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcella D. Walker.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walker, M.D., Cusano, N.E., Sliney, J. et al. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 44, 237–246 (2013). https://doi.org/10.1007/s12020-012-9819-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9819-4

Keywords

Search

Navigation